Status:
COMPLETED
The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
Lead Sponsor:
University Hospital, Gentofte, Copenhagen
Collaborating Sponsors:
University of Copenhagen
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in ...
Eligibility Criteria
Inclusion
- Caucasians over 18 years with type 1 diabetes (WHO criteria)
- Arginine test without rise in plasma C-peptide
- Normal blood Hemoglobin
- Informed consent
Exclusion
- Liver disease
- Diabetic nephropathy
- Treatment with medications unpausable for 12 hours
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00732602
Start Date
January 1 2008
Last Update
February 13 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, Gentofte
Hellerup, Capital Region, Denmark, 2900